The role of oxidative stress in hemorrhagic stroke and restorative effects of Mexidol

Voronina T.A.; Kraineva V.A.; Zolotov N.N.; Kotel’nikova S.O.; Val’dman E.A.

doi:https://doi.org/10.17116/jnevro202212208265

Voronina T.A.

Zakusov Institute of Pharmacology

SPIN RSCI: 5766-3452
Scopus AuthorID: 7103337584
ResearcherID: A-5990-2017
ORCID: 0000-0001-7065-469X

Kraineva V.A.

Zakusov Institute of Pharmacology

Zolotov N.N.

Zakusov Institute of Pharmacology

Kotel’nikova S.O.

Zakusov Institute of Pharmacology

Val’dman E.A.

Zakusov Institute of Pharmacology

The role of oxidative stress in hemorrhagic stroke and restorative effects of Mexidol

Authors:

Voronina T.A., Kraineva V.A., Zolotov N.N., Kotel’nikova S.O., Val’dman E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8‑2): 65‑71

DOI: 10.17116/jnevro202212208265

Read: 2482 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Voronina TA, Kraineva VA, Zolotov NN, Kotel’nikova SO, Val’dman EA. The role of oxidative stress in hemorrhagic stroke and restorative effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8‑2):65‑71. (In Russ.)
https://doi.org/10.17116/jnevro202212208265

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

Identification of the role of oxidative stress in the development of disorders that occur in hemorrhagic stroke (HS, post-traumatic intracerebral hematoma), and the study of the effects of Mexidol on neurological and cognitive deficits in HS with an analysis of the relationship between the therapeutic effects of the drug in HS with its antioxidant effect.

MATERIAL AND METHODS

The study was carried out on mature outbred male rats weighing 260—280 g. HS was created by destruction of the brain tissue in the area of the capsula interna, with the introduction of blood into the site of injury. On the 1^st, 7^th, and 14^th days after HS modeling, death, neurological deficits (McGrow scale, rotating rod), convulsive manifestations, and cognitive impairment were recorded in rats; blood plasma and homogenates of the cerebral cortex of rats. Mexidol was administered after the HS operation: first at a dose of 150 mg/kg, intraperitoneally, for 3 days and then 75 mg/kg, orally (from the 4^th to the 14^th day).

RESULTS

Mexidol in rats with HS significantly increases the survival rate of animals, reduces the manifestations of neurological deficits according to the McGrow scale (playpen movements, paresis of 1—4 limbs, paralysis of the lower limbs, lateral position), eliminates individual motor convulsive manifestations, restores impaired coordination of movements (rotating rod test) and improves, impaired HS, learning and memory processes. Mexidol normalizes the concentration of TBA-active products in the blood of animals and homogenates of the cerebral cortex of rats, both a day and 7 days after HS modeling.

CONCLUSION

The data obtained indicate the involvement of oxidative stress as a chain of pathogenesis in the development of disorders in HS and the ability of Mexidol to alleviate neurological deficits, convulsive manifestations and cognitive impairment in HS, which is accompanied by a decrease in oxidative stress. All this justifies the importance of the use of Mexidol in patients with hemorrhagic stroke, posttraumatic intracerebral hematoma and determines the features of its therapeutic effects.

Keywords:

hemorrhagic stroke

intracerebral hematoma

oxidative stress

Mexidol

neurological deficit

seizures

cognitive impairment

Authors:

Voronina T.A.

Zakusov Institute of Pharmacology

SPIN RSCI: 5766-3452
Scopus AuthorID: 7103337584
ResearcherID: A-5990-2017
ORCID: 0000-0001-7065-469X

Kraineva V.A.

Zakusov Institute of Pharmacology

Zolotov N.N.

Zakusov Institute of Pharmacology

Kotel’nikova S.O.

Zakusov Institute of Pharmacology

Val’dman E.A.

Zakusov Institute of Pharmacology

Received:

04.05.2022

Accepted:

06.05.2022

Close metadata

References:

World Health Organization: Top 10 causes of death. WHO. 2018. Accessed March 15. https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128. https://doi.org/10.1016/S0140-6736(12)61728-0
Gusev EI, Skvortsova VI, Stakhovskaia LV. Epidemiology of stroke in Russia. Zhurnal Nevrologii iPsikhiatrii im. S.S. Korsakova. 2003;8:4-9. (In Russ.).
Stroke. Guide for doctors. Edited by Stakhovskaya L.V., Kotov S.V. 2-e ed., rev.and extra. M.: OOO «Medical informative agency»; 2018. (In Russ.).
Stroke: modern technologies of diagnostic and treatment: A guide for doctors. Ed. by Piradov MA,Tanashian MM, Maksimova MYu. M.: MEDpress-inform; 2018. (In Russ.).
Ivanova GE, Melnikova EV, Levin OS, et al. Current issues in the rehabilitation of stroke patients against the background of COVID-19. Resolution of the Council of Experts. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8-2):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012008281
Machinskiy PA, Plotnikova NA, Ul’yankin VE, et al. Comparative characteristics of the ischemic and hemorrhagic stroke morbidity indicators in Russia. University proceedings. Volga region. Medical sciences. 2019;50(2):112-132. (In Russ.). https://doi.org/10.21685/2072-3032-2019-2-11
Gusev EI, Skvorcova VI. Ishemiya golovnogo mozga.M.: Medicina. 2007. (In Russ.).
Saver JL. Time Is Brain — Quantified. Stroke. 2006;37(1):263-266. https://doi.org/10.1161/01.STR.0000196957.55928.ab
Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinic, treatment). M.: AST. 2018. (In Russ.).
Fedin AI, Saverskaya EN, Badalyan KR. Multimodal therapeutic strategies in the treatment of cerebrovascular disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(12):112-118. (In Russ.). https://doi.org/10.17116/jnevro2021121121112
Liu S, Levine SR, Winn HR. Targeting ischemic penumbra: part I — from pathophysiology to therapeutic strategy. J. Exp. Stroke Transl. Med. 2010;3(1):47-55.
Bogolepova AN. The role of oxidative stress in the development of vascular cognitive disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(8):1-7. (In Russ.). https://doi.org/10.17116/jnevro2020120081133
Tashanyan MM. Cerebrovascular pathology and metabolic syndrome. M.: AST. 2019. (In Russ.).
Yang Q, Huang Q, Hu Z, et al. Potential neuroprotective treatment of stroke: excitotoxicity, oxidative stress, and inflammation. Front. Neurosci. 2019;13:1036-1039. https://doi.org/10.3389/fnins.2019.01036
Chamorro Á, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: Targeting excitotoxicity, oxidative and nitrosative stress, inflammation. Lancet Neurol. 2016;15(8):869-881. https://doi.org/10.1016/S1474-4422(16)00114-9
Voronina TA. Antioxidant Mexidol. The basic neuropsychotropic effects and mechanism of action. Psychopharmakol.Biol. Narkol. 2001;1(1):2-12. (In Russ.).
Voronina TA. Mexidol. Domestic drug of a new generation, main effects, mechanism of action, application. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2003;105(5):34-38. (In Russ.).
Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;180(6):1-4. (In Russ.).
Voronina TA. Pioner antioksidantnoy neyroprotektsii. 20 let v klinicheskoy praktike. Rossiyskiy Meditsinskiy Zhurnal. Nevrologiya. 2016;7:434-438. (In Russ.).
[Dumaev KM, Voronina TA, Smirnov LD. Antioxidants in the prevention and therapy of Central nervous system pathologies. M.: Publishing House of the Institute of Biomedical Chemistry of the Russian Academy of Sciences; 1995. (In Russ.).
Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, et al. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2006;106(18):47-54. (In Russ.).
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Kovalchuk VV. Theoretical prerequisites and practical aspects of adequate management and effective rehabilitation of patients after stroke. M.: AST; 2021;345. (In Russ.).
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Order of the Ministry of Health of the Russian Federation dated December 29, 2012 № 1740n «On approval of the standard for specialized medical care for cerebral infarction». (In Russ.). Accessed 15.03.2022 https://www.rosminzdrav.ru/documents/8970
Clinical recommendations «Ischemic stroke and transient ischemic attack in adults». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/171_2
Kraineva VA. The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke. Bulletin of Experimental Biology and Medicine.2006;1:40-44. (In Russ.).
Voronina TA, Ostrovskaya RU, Garibova TL. Guidelines for the experimental (preclinical) study of new pharmacological substances. Guidelines for the preclinical study of drugs with a nootropic type of action. M: GrifandK; 2012;1:276-296. (In Russ.).
Makarenko FN, Kositsyn NS, Pasikova NV, et al. Simulation of local cerebral hemorrhage in different brain structures of experimental animals. Zhurnal Vysshei Nervnoi Deyatelnosti imeni I.P.Pavlova. 2002;52(6):765-768. (In Russ.).
McGrow CP, Pashayan AG, Wendel OT. Cerebral infarction in the Mongolian gerbil exacerbated by phenoxybenzamine treatment. Stroke. 1976;7:5:485-8. https://doi.org/10.1161/01.str.7.5.485
Vatassery GT, Sheridan MA, Krezowski AM, et al. Use of the Sulfo-Phospo-Vanillin Reaction in a Routine Method for Determining Total Lipids in Human Cerebrospinal Fluid. Clin.Biochem. 1981;14(1):21-24. https://doi.org/10.1016/0009-9120(81)90120-x
Bligh EG, Dyer VJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959;37(8):911-917. https://doi.org/10.1139/o59-099
Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(4):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012004181
Lukyanova LD. Signaling mechanisms of hypoxia. M.: RAS; 2019. (In Russ.).
Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(1):55-61. (In Russ.). https://doi.org/10.17116/jnevro202012001162
Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39. (In Russ.).